Amelioration of Osteoarthritis Through Salicylic Acid Nano-Formulated

Jul 15, 2026

Upload by Anda

Osteoarthritis involves chronic cartilage degeneration driven by inflammatory mediators and catabolic enzymes that disrupt cartilage extracellular matrix homeostasis, with NF-κB signaling amplifying production of degradative and pro-inflammatory factors. Current NSAID therapies reduce pain but carry serious systemic side effects, motivating intra-articular delivery strategies. Salicylic acid, an aspirin metabolite with anti-inflammatory activity via COX-2/PGE2 and NF-κB inhibition, is explored in nano-formulated systems to prolong joint retention, enhance ECM penetration, enable targeted chondrocyte delivery, and achieve controlled long-acting release for sustained therapeutic effects.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

Applied Materials Today 37 (2024) 102102 Contents lists available at ScienceDirect Applied Materials Today journal [homepage: www.elsevier.com/locate/apmt](homepage: www.elsevier.com/locate/apmt) | Amelioration of osteoarthritis through salicylic acid nano-formulated self-therapeutic prodrug for the prolonged launch of salicylic acid to damaged cartilage<br>Ronghua Jin a, \#, Jialin Lib, \#, Biyi Huang a, \#, Jiayu Lua, Ju Huang a, Lingjun Wu a, Xifeng Moa, Yu Lia, Bo Sua, Alu Ouyanga, Hui Wang a, *, Ling Fan c, *, Ping He a, *<br>a Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, College of Pharmacy, Guangxi Medical University, Nanning 530021, China b Department of Pharmacy, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545007, China<br>c Key laboratory of Chemistry and Engineering of Forest Products, State Ethnic Affairs Commission, Guangxi Key Laboratory of Chemistry and Engineering of Forest Products, Guangxi Collaborative Innovation Center for Chemistry and Engineering of Forest Products, School of chemistry and chemical engineering, Guangxi Minzu University, Nanning 530006, China | | | | --- | --- | --- | | A R T I C L E I N F O | | A B S T R A C T | | Keywords:<br>Self-therapeutic prodrug Poly-salicylic acid Salicylic acid Inflammation Osteoarthritis | | As the most prevalent disease globally and with a lack of efficient therapeutic drugs, there is a need for novel strategies to treat osteoarthritis (OA). One approach being explored is the usage of biodegradable polymers as drug-delivery systems for OA treatment. However, a limitation of these polymeric drug carriers is that they do not possess therapeutic efficacy themselves. To address this issue, a new strategy has been developed using an aspirin-like oligomer called poly (salicylic acid) (PSA). The oligomer is synthesized through the self-esterification of salicylic acid (SA), which is a non-steroidal anti-inflammatory drug (NSAID) commonly used to relieve pain and inflammation associated with OA. Self-assembled PSA nanoparticles (PSA NPs) possess a distinctive capability to dynamically modulate the release rate of SA through the manipulation of their morphology. Crucially, SA, as the degradation product of the PSA NPs, has been substantiated to possess a demonstrated capability for capturing reactive oxygen species (ROS). In vitro studies have demonstrated the negligible toxicity of PSA NPs against SW1353 cells. Moreover, in vivo results have indicated that intra-articular injection of PSA NPs resulted in prolonged joint retention and significant alleviation of OA lesions in mice. Both in vitro and in vivo investigations have proved the capacity of PSA NPs to attenuate inflammation and restore the balance of cartilage extracellular matrix (ECM) metabolism through the inhibition of COX-2 and NF-κB p65 expressions. These compelling results suggest that the PSA NPs hold promising potential as an effective therapeutic strategy for

Jul 15, 2026

Upload by Anda